Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078].
ESMO Open
; 6(3): 100137, 2021 Jun.
Article
in En
| MEDLINE
| ID: mdl-34144775
Full text:
1
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
ESMO Open
Year:
2021
Type:
Article
Affiliation country:
United kingdom